Showing 541 - 560 results of 99,941 for search '(( 5 non decrease ) OR ( 5 ((((nn decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.48s Refine Results
  1. 541
  2. 542
  3. 543
  4. 544
  5. 545

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  6. 546
  7. 547
  8. 548
  9. 549
  10. 550

    Human SHBG mRNA Translation Is Modulated by Alternative 5′-Non-Coding Exons 1A and 1B by Tomàs Pinós (238160)

    Published 2010
    “…LNCaP prostate cancer cells transfected with several SHBG constructs containing exons 2 to 8 but lacking the 5′UTR sequence did show SHBG translation, whereas inclusion of the 5′UTR sequences of either exon 1A or 1B caused a dramatic decrease in SHBG protein levels. …”
  11. 551

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  12. 552
  13. 553
  14. 554

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  15. 555
  16. 556

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  17. 557
  18. 558
  19. 559

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  20. 560